ReviewCurrent neuropharmacology2025
Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic.
Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of Dexmedetomidine Treatment After Cerebral Ischemia/Reperfusion on Apoptosis and Oxidative Stress: A Rat Model.Life (Basel, Switzerland) · 2026Article
- Therapeutic Potentials of Anesthetics.Current neuropharmacology · 2026Article
- Dexmedetomidine regulates sleep rhythm and alleviates neuroinflammation in rats under high-altitude hypoxia.Journal of physiology and biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Neuropsychiatric disorders encompass a range of conditions resulting from various dysfunctions within the nervous system, manifesting in diverse neurological impairments. These disorders, including depression, schizophrenia, anxiety, and Alzheimer's disease, impose significant economic and psychological burdens on both individuals and society overall. Recent clinical and preclinical studies have highlighted that dexmedetomidine (Dex), a highly selective α2 adrenergic receptor agonist, may offer therapeutic benefits beyond its well-known sedative properties. Dex has demonstrated neuroprotective effects, including anti-inflammatory and anti-apoptotic effects, as well as contributing to maintaining the integrity of the blood-brain barrier. Additionally, clinical observations suggest that Dex could be beneficial in managing neuropsychiatric disorders, with fewer side effects compared to traditional antipsychotics in both rodent and human studies. This review presents a comprehensive overview of the preclinical and clinical evidence supporting the therapeutic efficacy of Dex in neuropsychiatric disorders. We also discuss the underlying mechanisms of its effect and point out future research directions to further investigate Dex's role in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.